title: Central nervous system directed therapy in acute lymphoblastic leukaemia.
abstract: CNS-directed treatment is an essential component of therapy for both children and adults with acute lymphoblastic leukaemia. The choice between combinations of i.t. drugs, radiotherapy and high-dose systemic chemotherapy is not a clear one and will depend on the age of the patient, the type of leukaemia and indeed the available treatment facilities. A plea is made for any prospective trials of CNS-directed therapy to incorporate formal assessment of neuropsychological performance, and in the young child, of growth and pubertal progression.
authors: Institute of Child Health, London, UK.
authors: J M
authors: JM
authors: Chessells
mesh_terms: D000305:Adrenal Cortex Hormones / Q000493:pharmacokinetics / Q000627:therapeutic use; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000009:adverse effects; D016371:Cranial Irradiation / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006130:Growth Disorders / Q000209:etiology; D006801:Humans; D007278:Injections, Spinal; D017254:Leukemic Infiltration / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy*; D008297:Male; D008578:Meninges / Q000473:pathology*; D001523:Mental Disorders / Q000209:etiology; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009381:Neoplasms, Radiation-Induced; D016609:Neoplasms, Second Primary; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology* / Q000628:therapy; D011446:Prospective Studies; D011788:Quality of Life; D011832:Radiation Injuries / Q000209:etiology; D012307:Risk Factors; D015996:Survival Rate; D017741:Survivors; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D003561:Cytarabine; D008727:Methotrexate